Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Sagimet Biosciences Inc. Series A Common Stock(SGMT)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for SGMT
10/27/2026: SGMT (4-star) is currently NOT-A-BUY. Pass it for now.
Sagimet Biosciences is a clinical-stage biotechnology company developing FASN inhibitors, with a primary focus on treating MASH. The company's core strength lies in its specialized platform and promising mid-stage clinical data for its lead candidate, denifanstat. The main investment story centers on the potential for this novel therapeutic to address a significant unmet medical need in a large, growing market. However, the company faces substantial risks, including the inherent uncertainty of clinical trials, intense competition from well-funded rivals, and the need for future financing. It is best suited for growth-oriented investors capable of managing high volatility and should be monitored for key clinical trial outcomes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | The company offers high-risk, high-reward potential based on clinical trial outcomes but lacks current revenue growth. |
| Momentum investor | Strong fit while signal remains positive | Momentum traders may find opportunities surrounding major clinical data releases and regulatory milestones. |
| Value investor | Weak fit | The company does not currently generate earnings or dividends, making it unsuitable for traditional value metrics. |
| Dividend investor | Weak fit | Sagimet does not pay dividends and is in a capital-intensive development phase. |
| Low-risk investor | Weak fit | High volatility inherent in clinical-stage biotech development presents risks unsuitable for low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical-stage biotech stocks are highly sensitive to trial results and news cycles. |
| Valuation risk | Medium / high | Valuations are often speculative and based on projected future success of drug candidates. |
| Competition risk (MASH therapy) | High | Numerous competitors are targeting the same MASH patient population with potentially more advanced or effective drugs. |
| Business quality | Medium | The business relies on the scientific success of a single lead platform. |
| Dividend income | Low / none | The company is not profitable and does not distribute cash to shareholders. |
| Execution risk | High | Failure to achieve regulatory approval or successfully commercialize denifanstat would be a major setback. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 244.72% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 10/27/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 738.87M USD | Price to earnings Ratio - | 1Y Target Price 27.91 |
Price to earnings Ratio - | 1Y Target Price 27.91 | ||
Volume (30-day avg) 1.5M shares | Beta 3.49 | 52 Weeks Range 4.50 - 11.45 | Updated Date 10/27/2026 |
52 Weeks Range 4.50 - 11.45 | Updated Date 10/27/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.27 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Clinical Development | Research and clinical trial advancement of FASN inhibitors. | The company currently spends money to develop drugs rather than selling them. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 441.12M | Price to Sales(TTM) 52.5 |
Enterprise Value 441.12M | Price to Sales(TTM) 52.5 | ||
Enterprise Value to Revenue 0.28 | Enterprise Value to EBITDA -1.93 | Shares Outstanding 70.34M | Shares Floating 56.57M |
Shares Outstanding 70.34M | Shares Floating 56.57M | ||
Percent Insiders 2.95 | Percent Institutions 77.24 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.